ALLMedicine™ Primary Central Nervous System Lymphoma Center
Research & Reviews 1,421 results
https://doi.org/10.3171/2020.9.JNS201980
Journal of Neurosurgery; Schellekes N, Barbotti A et. al.
Feb 26th, 2021 - Primary central nervous system lymphoma (PCNSL) is a rare CNS tumor with a poor prognosis. It is usually diagnosed by needle biopsy and treated mainly with high-dose chemotherapy. Resection is currently not considered a standard treatment option. ...
https://doi.org/10.1111/bjh.17357
British Journal of Haematology; Ferreri AJM, Calimeri T et. al.
Feb 23rd, 2021 - Reliable biomarkers are needed to avoid diagnostic delay and its devastating effects in patients with primary central nervous system (CNS) lymphoma (PCNSL). We analysed the discriminating sensitivity and specificity of myeloid differentiation prim...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7898756
BMC Cancer; Zhang Y, Zou D et. al.
Feb 23rd, 2021 - Establishing diagnostic and prognostic biomarkers of primary central nervous system lymphoma (PCNSL) is a challenge. This study evaluated the value of dynamic interleukin (IL)-10 cerebrospinal fluid (CSF) concentrations for prognosis and relapse p...
https://doi.org/10.1016/j.wneu.2021.02.059
World Neurosurgery; Barbaro M, Fine HA et. al.
Feb 22nd, 2021 - Neuro-oncology is a branch of medicine focused on the diagnosis and treatment of primary and secondary tumors of the nervous system as well as the neurologic complications of cancer and cancer treatments. In practice, neuro-oncologists require an ...
https://doi.org/10.1007/s11060-021-03708-8 10.1038/leu.2017.128 10.1200/JCO.2006.08.2941 10.1200/JCO.2003.09.139 10.1016/0022-3956(75)90026-6 10.1212/01.WNL.0000098892.33018.4C 10.1016/j.ijrobp.2010.05.003 10.3171/jns.2000.92.2.0261 10.1016/s2352-3026(15)00074-5 10.1016/S1470-2045(18)30747-2 10.3233/JAD-160248 10.1200/JCO.2003.04.172 10.1200/JCO.18.00306 10.1001/jama.1993.03500180078038 10.1016/S1470-2045(07)70384-4 10.1001/archneur.65.7.963 10.1038/leu.2016.334 10.1200/JCO.2003.07.080 10.2217/cns.13.5 10.1016/S1470-2045(10)70229-1
Journal of Neuro-oncology; van der Meulen M, Dirven L et. al.
Feb 21st, 2021 - To assess the value of the Mini-Mental State Examination (MMSE)-score at baseline in predicting survival in adult primary central nervous system lymphoma (PCNSL) patients. In the HOVON 105/ ALLG NHL 24 phase III study patients with newly-diagnosed...
Clinicaltrials.gov 1,439 results
https://doi.org/10.3171/2020.9.JNS201980
Journal of Neurosurgery; Schellekes N, Barbotti A et. al.
Feb 26th, 2021 - Primary central nervous system lymphoma (PCNSL) is a rare CNS tumor with a poor prognosis. It is usually diagnosed by needle biopsy and treated mainly with high-dose chemotherapy. Resection is currently not considered a standard treatment option. ...
https://doi.org/10.1111/bjh.17357
British Journal of Haematology; Ferreri AJM, Calimeri T et. al.
Feb 23rd, 2021 - Reliable biomarkers are needed to avoid diagnostic delay and its devastating effects in patients with primary central nervous system (CNS) lymphoma (PCNSL). We analysed the discriminating sensitivity and specificity of myeloid differentiation prim...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7898756
BMC Cancer; Zhang Y, Zou D et. al.
Feb 23rd, 2021 - Establishing diagnostic and prognostic biomarkers of primary central nervous system lymphoma (PCNSL) is a challenge. This study evaluated the value of dynamic interleukin (IL)-10 cerebrospinal fluid (CSF) concentrations for prognosis and relapse p...
https://doi.org/10.1016/j.wneu.2021.02.059
World Neurosurgery; Barbaro M, Fine HA et. al.
Feb 22nd, 2021 - Neuro-oncology is a branch of medicine focused on the diagnosis and treatment of primary and secondary tumors of the nervous system as well as the neurologic complications of cancer and cancer treatments. In practice, neuro-oncologists require an ...
https://doi.org/10.1007/s11060-021-03708-8 10.1038/leu.2017.128 10.1200/JCO.2006.08.2941 10.1200/JCO.2003.09.139 10.1016/0022-3956(75)90026-6 10.1212/01.WNL.0000098892.33018.4C 10.1016/j.ijrobp.2010.05.003 10.3171/jns.2000.92.2.0261 10.1016/s2352-3026(15)00074-5 10.1016/S1470-2045(18)30747-2 10.3233/JAD-160248 10.1200/JCO.2003.04.172 10.1200/JCO.18.00306 10.1001/jama.1993.03500180078038 10.1016/S1470-2045(07)70384-4 10.1001/archneur.65.7.963 10.1038/leu.2016.334 10.1200/JCO.2003.07.080 10.2217/cns.13.5 10.1016/S1470-2045(10)70229-1
Journal of Neuro-oncology; van der Meulen M, Dirven L et. al.
Feb 21st, 2021 - To assess the value of the Mini-Mental State Examination (MMSE)-score at baseline in predicting survival in adult primary central nervous system lymphoma (PCNSL) patients. In the HOVON 105/ ALLG NHL 24 phase III study patients with newly-diagnosed...
News 21 results
https://www.mdedge.com/hematology-oncology/article/210341/b-cell-lymphoma/primary-cns-lymphoma-r-chop-hits-back?channel=59374
Vanja Zeremski, MD, Thomas Fischer, MD
Oct 17th, 2019 - Primary central nervous system lymphoma (PCNSL) is a rare and aggressive form of non-Hodgkin lymphoma solely confined to the CNS. The majority of PCNSL histologically presents as diffuse large B-cell lymphoma (DLBCL).
https://www.mdedge.com/fedprac/avaho/article/206078/lymphoma-plasma-cell-disorders/review-radiologic-considerations/page/0/1?channel=263
Aug 7th, 2019 - Discussion The workup of altered mental status, focal neurologic deficits, headaches, or other neurologic conditions often begins with a noncontrast CT scan. On CT, PCNSL generally appears isodense to hyperdense to gray matter, but appearance is v.
https://www.mdedge.com/hematology-oncology/article/199565/b-cell-lymphoma/high-dose-mtx-based-chemo-well-tolerated-older?channel=59374
Will Pass
Apr 24th, 2019 - GLASGOW – Most older patients with primary central nervous system lymphoma (PCNSL) can tolerate high-dose methotrexate-based chemotherapy and achieve similar outcomes as younger and fitter patients, according to a retrospective analysis of 244 pat.
https://www.mdedge.com/hematology-oncology/article/197142/b-cell-lymphoma/rituximab-boosts-survival-primary-cns-lymphoma?channel=59374
Will Pass
Mar 22nd, 2019 - For patients with primary central nervous system lymphoma (PCNSL), adding rituximab to combination high-dose methotrexate and temozolomide significantly boosted the 5-year overall survival rate, according to a retrospective study. The triplet comb.
https://www.mdedge.com/hematology-oncology/article/190772/lymphoma-plasma-cell-disorders/new-pcnsl-guidelines-emphasize-importance?channel=49434
Jennie Smith
Dec 2nd, 2018 - Image by Michael Bonert Micrograph showing PCNSL New guidelines on the diagnosis and management of patients with primary central nervous system lymphoma (PCNSL) emphasize prompt diagnosis, aggressive treatment whenever possible, and multidisciplin.
